Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

6533b873fe1ef96bd12d579b

RESEARCH PRODUCT

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

Ferdinando Riccardi Carmela Mocerino Ivana Puliafito Elios Antonella Di Sarno Roberta Modica Giuseppe Badalamenti A. Bianco Chiara De Divitiis Antongiulio Faggiano Valentina Guarnotta Silvana Di Maio Lucia Tozzi Margaret Ottaviano Salvatore Tafuto Giovannella Palmieri Silvana Leo Pasquale Dolce Annamaria Colao

subject

Male Oncology medicine.medical_specialty High-dose somatostatin analogs; neuroendocrine tumors; PRRT; sequence of treatments; somatostatin analogues; targeted therapy Lung Neoplasms Databases Factual Settore MED/06 - Oncologia Medica Endocrinology Diabetes and Metabolism medicine.medical_treatment Antineoplastic Agents High-dose somatostatin analog Neuroendocrine tumors Octreotide Somatostatin analogue Targeted therapy Settore MED/13 - Endocrinologia Targeted therapy Endocrinology Neuroendocrine tumor Stomach Neoplasms Internal medicine Diabetes mellitus Intestinal Neoplasms Sequence of treatment medicine Humans Everolimus Retrospective Studies Chemotherapy Everolimus business.industry Disease Management Middle Aged medicine.disease Discontinuation Pancreatic Neoplasms Neuroendocrine Tumors Radionuclide therapy Female Observational study PRRT Somatostatin business medicine.drug

description

Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the main therapeutic sequences in G1−G2 NET. Methods: A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in NET. Median progression-free survival (PFS) was compared between therapeutic sequences, as well as the number and grade of side effects and the rate of dose reduction/treatment discontinuation. Results: Among 1182 patients with neuroendocrine neoplasia included in the ELIOS database, 131 G1–G2 gastroenteropancreatic, lung and unknown primary NET, unresectable or persistent/relapsing after surgery, treated with ≥2 systemic treatments, were included. Four main therapeutic sequences were identified in 99 patients: (A) somatostatin analogs (SSA) standard dose to SSA high dose (n = 36), (B) SSA to everolimus (n = 31), (C) SSA to chemotherapy (n = 17), (D) SSA to peptide receptor radionuclide therapy (PRRT) (n = 15). Median PFS of the second-line treatment was not reached in sequence A, 33 months in sequence B, 20 months in sequence C, 30 months in sequence D (p = 0.16). Both total number and severity of side effects were significantly higher in sequences B and C than A and D (p = 0.04), as well as the rate of dose reduction/discontinuation (p = 0.03). Conclusions: SSA followed by SSA high dose, everolimus, chemotherapy or PRRT represent the main therapeutic sequences in G1−G2 NET. Median PFS was not significantly different between sequences. However, the sequences with SSA high dose or PRRT seem to be better tolerated than sequences with everolimus or chemotherapy.

year	journal	country	edition	language
2019-01-01

10.1007/s12020-019-01894-0 http://hdl.handle.net/10447/367332